Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 801 to 810 of 1331 total matches.
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010 (Issue 1332)
days
Half-life 18-37 hours
Metabolism CYP2D6 and CYP3A4; 2 active
metabolites
Table 1 ...
The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone (Risperdal, and others).
Two Drugs for Weight Loss
The Medical Letter on Drugs and Therapeutics • Sep 03, 2012 (Issue 1398)
pressure, and
cause nervousness and insomnia.
LORCASERIN (Belviq) — Activation of the serotonin
2C ...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or...
Concentrated Insulin Glargine (Toujeo) for Diabetes
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
than
Lantus, resulting in more even activity throughout the
dosing period and a longer duration ...
The FDA has approved Toujeo (Sanofi), a more
concentrated form of insulin glargine containing 300
IU/mL compared to the 100 IU/mL in Lantus (Sanofi).
Lantus is nearing the end of its patent protection in the
US, and biosimilars are expected to become available.
Byvalson - A Beta Blocker/ARB Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016 (Issue 1503)
activity. Beta3
activation induces vasodilation through endothelial
release of nitric oxide. Valsartan ...
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only combination product that
contains nebivolol, and the first to combine a beta
blocker with an ARB.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
, or
bulimia should not take bupropion
▶ Primarily metabolized by CYP2B6 to
hydroxybupropion, its most active ...
View the Expanded Table: Some Drugs for Smoking Cessation
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
OF ACTION — Bempedoic acid is
activated to bempedoic acid-CoA by very-long-chain
acyl-CoA synthetase 1 ...
The FDA has approved the oral adenosine triphosphate-citrate
lyase (ACL) inhibitor bempedoic acid for
use alone (Nexletol – Esperion) and in a fixed-dose
combination with the cholesterol absorption inhibitor
ezetimibe (Nexlizet) as an adjunct to diet and maximally
tolerated statin therapy in adults with heterozygous
familial hypercholesterolemia (HeFH) or established
atherosclerotic cardiovascular disease (ASCVD) who
require additional lowering of LDL-cholesterol (LDL-C).
Bempedoic acid is the first ACL inhibitor to be approved
in the US.
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
as inactive
metabolites)
Half-life (terminal) 152 hours
ANTIFUNGAL ACTIVITY ― Rezafungin, a derivative ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug to become available
in the US in more than 15 years for treatment of
systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4 doi:10.58347/tml.2024.1705d | Show Introduction Hide Introduction
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
Cannabis and Cannabinoids
Cannabis (marijuana) contains more than 60
pharmacologically active ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
.
BISPHOSPHONATES — These nonhormonal drugs
decrease bone resorption by binding to active sites
of bone remodeling ...
Pharmacologic treatment is recommended for
postmenopausal women who have bone density
T-scores (standard deviations from normal mean
values in the spine, femoral neck, total hip, or distal
radius) of -2.5 or below, T-scores between -1.0 and
-2.5 with a history of fragility (low-trauma) fracture
of the hip or spine, or T-scores between -1.0 and
-2.5 with a FRAX 10-year probability of ≥3% for hip
fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12 doi:10.58347/tml.2024.1706a | Show Introduction Hide Introduction
Methylphenidate Revisited
The Medical Letter on Drugs and Therapeutics • May 06, 1988 (Issue 765)
of motor activity, impulsivity, and inattention; boys are affected
more often than girls (R McGee et al, J ...
Methylphenidate (Ritalin and others), a Schedule II controlled substance in the USA, is a short-acting central-nervous-system stimulant widely used for treatment of children with school performance or behavior problems, or what is now called Attention Deficit-Hyperactivity Disorder, or AD-HD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, third ed., revised [DSM-III R], Washington, DC:authors, 1987, p 50). Some studies have estimated that more than 3% of elementary school students are taking methylphenidate, and one parents' group has brought a...